헬리코박터 파일로리 진단 시장 : 검사 유형별, 제품 유형별, 기술별, 최종 사용자별 - 시장 예측(2026-2032년)

The Helicobacter Pylori Diagnostics Market was valued at USD 906.04 million in 2025 and is projected to grow to USD 981.87 million in 2026, with a CAGR of 10.04%, reaching USD 1,770.78 million by 2032.

A definitive overview of Helicobacter pylori diagnostics highlighting clinical implications, diagnostic modalities, patient pathways, and the strategic importance of accurate testing across care settings

Helicobacter pylori remains a central concern in gastrointestinal medicine due to its established role in chronic gastritis, peptic ulcer disease, and as a risk factor for gastric malignancy. Accurate, timely diagnosis is therefore a clinical imperative that affects therapy selection, eradication monitoring, and broader public health efforts. Diagnostics for H. pylori span invasive and noninvasive approaches, each offering distinct trade-offs between sensitivity, specificity, turnaround time, and resource intensity.

Clinical laboratories and care providers must consider test performance characteristics in the context of patient presentation, prior treatment history, and the intended use of results-whether for initial diagnosis, confirmation of eradication, or surveillance for resistance. Recent years have seen the integration of molecular methods alongside traditional histology and culture, while noninvasive antigen and breath tests remain central to outpatient evaluation. These modalities are deployed across varied settings from primary care clinics to large hospital systems, with each setting imposing unique operational constraints and procurement priorities.

As diagnostics evolve, the interplay between laboratory workflows, clinician preferences, and payer policies becomes increasingly consequential. Effective diagnostic strategies require harmonization of specimen collection protocols, quality controls, and clinician education to ensure appropriate test selection and interpretation. Furthermore, diagnostic choice directly influences antibiotic stewardship efforts and downstream clinical outcomes, reinforcing the need for diagnostic pathways that are both clinically robust and operationally feasible.

Transformative technological, operational, and digital shifts reshaping Helicobacter pylori diagnostics with implications for clinical decision making and market dynamics

The diagnostic landscape for Helicobacter pylori is undergoing a rapid transformation driven by advances in molecular technologies, point-of-care instrument miniaturization, and improved noninvasive testing performance. Molecular platforms are expanding from centralized laboratory PCR systems to near-patient isothermal approaches and real-time PCR instruments that provide both detection and antimicrobial resistance markers. At the same time, enhanced immunoassays and high-performance stool antigen tests are refining noninvasive screening and post-treatment confirmation.

Concurrently, endoscopy technology and image-enhancement algorithms are improving visual detection and enabling targeted biopsies that increase diagnostic yield. Artificial intelligence tools are beginning to support lesion recognition and procedural standardization, which, together with enhanced staining and histological techniques, strengthen the role of invasive diagnostics where clinically indicated. These shifts facilitate more precise therapeutic decisions and better alignment with stewardship goals.

Operationally, the movement toward decentralization is reshaping procurement and service delivery. Point-of-care tests reduce time-to-result and can be integrated into ambulatory workflows, while analyzer equipment continues to add throughput and multiplexing capabilities. The convergence of digital health, telemedicine, and laboratory connectivity also supports more seamless result sharing and follow-up, thereby improving adherence to eradication protocols. Taken together, these technological and operational shifts create new commercial and clinical opportunities while raising fresh challenges around validation, quality assurance, and reimbursement.

Assessing how the 2025 United States tariff measures have reshaped supply chains, manufacturing decisions, and procurement strategies across Helicobacter pylori diagnostics

The introduction of United States tariffs in 2025 has produced multifaceted impacts on the diagnostics ecosystem, influencing component sourcing, pricing strategies, and supply chain architecture. Tariff-driven cost pressures on imported consumables, reagents, and analyzer components have led many manufacturers and clinical laboratories to re-evaluate vendor relationships and inventory management practices. In turn, procurement teams have adopted longer lead times and increased buffer stocks to mitigate potential supply disruptions, which affects working capital and operational logistics.

At the product level, tariffs have incentivized local manufacturing or nearshoring initiatives for high-volume consumables and assay kits. Some diagnostic firms responded by qualifying additional domestic contract manufacturers or by relocating assembly lines to jurisdictions less affected by trade barriers. These strategic moves are intended to protect continuity of supply and to reduce exposure to tariff volatility, though they require investment in quality systems, regulatory permits, and supplier audits.

Healthcare providers face competing pressures: the need to maintain clinically validated testing algorithms while managing budgetary constraints. Laboratories and hospitals have scrutinized cost-per-test and total cost of ownership for analyzers, weighing capital acquisition against reagent dependency and service agreement terms. Smaller clinics and ambulatory centers, often with tighter margins, have had to consider consolidated purchasing through group purchasing organizations or long-term supply agreements to preserve access to essential diagnostics.

Regulatory compliance and documentation have become more salient as provenance and traceability requirements increase for domestically sourced assays. Suppliers prioritizing diversified supply chains have also emphasized transparent quality controls and rapid regulatory filings to shorten time-to-market for alternatives. Overall, the tariff environment has catalyzed structural changes across manufacturing, procurement, and clinical adoption pathways, prompting stakeholders to balance resilience investments against near-term operational costs.

Segment-driven insights revealing where test types, product formats, end-user needs, and technology categories converge to shape diagnostic adoption and investment priorities

Insights derived from granular segmentation illuminate where clinical demand converges with technological capability and where strategic investments will yield the greatest returns. Across test types, histology remains a cornerstone in invasive diagnostic workflows and is typically executed with hematoxylin and eosin staining complemented by special stains to enhance organism visualization. Molecular testing has broadened its footprint, with isothermal amplification providing rapid near-patient detection, conventional polymerase chain reaction used in reference laboratories for high-sensitivity assays, and real-time PCR offering quantitation and resistance marker identification. Rapid urease tests retain utility in endoscopy suites and are commonly available as Clo test formats and PyloriTek test variants that prioritize speed and ease of interpretation. Serology continues to play a role in epidemiologic studies and specific clinical contexts through enzyme-linked immunosorbent assays and lateral flow assays, although it is less favored for post-treatment confirmation. Stool antigen testing, delivered via enzyme immunoassays or lateral flow immunoassays, supports noninvasive diagnosis and eradication verification, while urea breath tests, available as 13C and 14C variants, remain a highly accurate noninvasive option often used in primary care and specialist settings.

When evaluating product types, consumables dominate routine testing due to the continual need for kits, reagents, and test strips. Kits span PCR kits for molecular detection, rapid urease test kits tailored for procedural use, serology kits optimized for batch testing, stool antigen test kits suitable for outpatient specimen processing, and urea breath test kits designed for breath analyzer compatibility. Instruments encompass analyzer equipment and endoscopy systems, with analyzer categories including breath test analyzers, immunoassay analyzers, and PCR instruments that vary by throughput, automation level, and connectivity. Endoscopy systems remain critical for invasive diagnostics and therapeutic interventions, driving demand for integrated imaging and biopsy capabilities.

End users introduce operational nuance that shapes product preference and purchasing behavior. Ambulatory care centers, comprised of community health centers and outpatient clinics, prioritize rapid, easy-to-administer noninvasive tests and durable point-of-care solutions. Clinics, whether primary care or specialty-focused, balance cost and clinical performance to support routine screening and follow-up. Diagnostic laboratories, split between commercial and reference laboratories, favor high-throughput molecular instruments and automated immunoassay platforms that enable scalable testing and multiplex capacity. Hospitals, including both large tertiary centers and smaller community facilities, require a hybrid mix: robust endoscopy capabilities for invasive diagnosis and a portfolio of analyzers and consumables that support inpatient and outpatient workflows.

Technology segmentation distinguishes invasive modalities such as culture, histology, and rapid urease testing from noninvasive approaches like antigen testing, breath testing, molecular assays, and serology. Notably, breath testing is contextualized to include both stool antigen test approaches and urea breath tests in applied clinical pathways, reflecting how noninvasive sample types and analytic platforms can overlap in operational deployment. This nuanced segmentation underscores the need for vendors to align product design and commercialization strategies with the distinct workflow requirements of each end-user segment and testing environment.

Regionally differentiated diagnostic dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific revealing adoption, infrastructure, and policy implications for testing strategies

Regional dynamics exert a powerful influence on diagnostic choice, reimbursement, and adoption pathways, with distinct patterns emerging across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, mature laboratory networks and advanced reimbursement frameworks favor the uptake of high-sensitivity molecular assays and integrated analyzer platforms. Centralized laboratories and reference testing services support complex molecular workflows, while ambulatory care and outpatient clinics increasingly adopt point-of-care solutions to shorten time-to-treatment. This region also emphasizes antimicrobial stewardship programs and post-treatment confirmation protocols that influence test selection.

In Europe, the Middle East & Africa, regulatory diversity and variable healthcare infrastructure create a heterogeneous marketplace. Some countries demonstrate rapid adoption of noninvasive testing and breath analyzers supported by public health screening initiatives, whereas others rely on traditional histology and endoscopy-based diagnostics due to clinician preference or resource constraints. Reimbursement policies and national guidelines in these markets can materially alter the commercial landscape, necessitating localized evidence generation and stakeholder engagement to achieve adoption.

The Asia-Pacific region presents a complex mix of high disease prevalence in certain subregions, growing domestic manufacturing capabilities, and rapid technological adoption. Noninvasive diagnostics such as stool antigen tests and urea breath tests are particularly valuable in primary care settings, and there is notable investment in both molecular platforms and local production of consumables. Private healthcare growth and expanding diagnostic laboratory networks are accelerating the adoption of automated analyzers and multiplex molecular assays, while governmental public health efforts in some countries prioritize screening and eradication programs that influence procurement and implementation strategies.

Company-level perspectives emphasizing product performance, partnership models, supply chain resilience, and clinical evidence strategies that determine competitive positioning in H pylori diagnostics

Competitive dynamics in the diagnostics landscape favor companies that combine robust assay performance with reliable supply chains, regulatory expertise, and clear clinical value propositions. Established instrument manufacturers maintain an advantage through installed base, service networks, and integrated software for result management, while agile molecular firms differentiate via rapid assay development cycles and resistance detection capabilities. Kit and reagent suppliers that can demonstrate reproducible performance across specimen types and that invest in quality certification are positioned to win long-term contracts with commercial and hospital laboratories.

Strategic partnerships and co-development agreements between instrument vendors and assay developers are increasingly common as firms seek to offer end-to-end solutions that simplify adoption for laboratory customers. Contract manufacturing organizations that can scale production while meeting stringent quality standards are valuable partners, particularly in contexts where tariff pressures and supply chain resilience are priorities. Additionally, companies that provide comprehensive training, technical support, and connectivity solutions to integrate test results into electronic health records gain traction with institutional purchasers.

Innovation pipelines focused on multiplexing, resistance genotyping, and simplified sample-to-answer workflows attract attention from both clinicians and procurement teams. Firms that invest in robust clinical validation studies and that engage with key opinion leaders to generate real-world evidence strengthen their market positioning. Finally, organizations that proactively manage regulatory filings and demonstrate compliance across major regions reduce adoption friction and accelerate commercial rollouts.

Actionable strategic recommendations for diagnostic manufacturers, laboratories, and health systems to accelerate adoption, improve resilience, and maximize clinical value of H pylori testing

Industry leaders should consider a set of pragmatic actions to capitalize on emerging diagnostic trends while mitigating operational risk. First, prioritize investment in noninvasive molecular and high-performance antigen assays that streamline workflows and reduce reliance on invasive procedures, while ensuring assays are validated for intended clinical uses. Second, diversify supply chains by qualifying additional suppliers and by evaluating nearshoring or regional manufacturing partnerships to reduce exposure to trade-related disruptions and to improve lead times.

Third, build payer and health system engagement strategies that articulate the clinical and economic value of accurate diagnostics, including the role of testing in reducing unnecessary antibiotic use and in preventing downstream complications. Fourth, develop integrated solutions that pair analyzers with consumable kits and digital connectivity to enhance data flow, enable quality controls, and support clinician decision making. Fifth, invest in antimicrobial resistance testing capabilities and corresponding clinician education to reinforce stewardship and to provide actionable therapeutic guidance.

Sixth, pursue strategic collaborations with endoscopy system providers and laboratory automation partners to create comprehensive diagnostic pathways that align with institutional workflows. Seventh, emphasize regulatory preparedness and rapid evidence generation through multicenter validation studies to facilitate market entry across diverse geographies. Finally, implement flexible commercial models-such as reagent rental, subscription-based pricing, or outcome-linked agreements-to address buyer preferences and to share risk with customers during adoption cycles.

Comprehensive mixed-methods research approach combining expert interviews, workflow analysis, regulatory review, and technology assessment to validate diagnostic insights and implications

The research underpinning this analysis employed a mixed-methods approach that integrates primary qualitative insights with secondary evidence synthesis and technical assessment. Primary research included structured interviews with clinicians, laboratory directors, procurement officers, and industry executives to capture real-world diagnostic workflows, purchasing rationales, and unmet needs. Supplemental site visits and workflow mapping provided contextual understanding of specimen handling, result reporting, and integration points for point-of-care and laboratory systems.

Secondary research encompassed peer-reviewed literature, clinical guidelines, regulatory documentation, and technical product specifications to validate assay performance characteristics and to compare technology platforms. Technology assessments evaluated analytical sensitivity, specificity, turnaround time, throughput, and operational footprint. Regulatory pathways were reviewed across major jurisdictions to identify evidence requirements and approval timelines.

Data triangulation was applied to reconcile discrepancies between primary and secondary sources and to ensure robustness of conclusions. Where available, clinical validation studies and real-world performance data informed assessments of diagnostic utility and suitability for different end-user settings. The methodology also acknowledges limitations, including potential variability in laboratory practices and regional guideline differences, and it emphasizes that insights are intended to support strategic decision-making rather than serve as prescriptive clinical guidance.

Conclusive perspective on the strategic convergence of diagnostic innovation, operational resilience, and clinical stewardship shaping the future of H pylori testing

Diagnostics for Helicobacter pylori are at an inflection point where enhanced molecular capabilities, improved noninvasive tests, and evolving clinical pathways converge to enable more precise patient management. Stakeholders across the ecosystem-manufacturers, laboratories, clinicians, and health systems-must adapt to technological advances while managing supply chain complexities and shifting reimbursement landscapes. Strategic alignment between product design, evidence generation, and end-user needs will be critical to realizing the clinical and commercial potential of next-generation diagnostics.

Looking ahead, success will hinge on the ability to deliver clinically meaningful, operationally sustainable solutions that integrate with care pathways and support antimicrobial stewardship. By prioritizing resilience in sourcing, investing in clinically validated technologies, and engaging payers and providers with clear value propositions, organizations can both improve patient outcomes and secure competitive advantage. The evolving landscape presents significant opportunities for those who combine technical excellence with pragmatic commercialization strategies that respond to regional and end-user heterogeneity.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Helicobacter Pylori Diagnostics Market, by Test Type

• 8.1. Histology
  • 8.1.1. Hematoxylin And Eosin Staining
  • 8.1.2. Special Stains
• 8.2. Molecular Test
  • 8.2.1. Isothermal Amplification
  • 8.2.2. Polymerase Chain Reaction
  • 8.2.3. Real Time Polymerase Chain Reaction
• 8.3. Rapid Urease Test
  • 8.3.1. Clo Test
  • 8.3.2. PyloriTek Test
• 8.4. Serology Test
  • 8.4.1. Enzyme Linked Immunosorbent Assay
  • 8.4.2. Lateral Flow Assay
• 8.5. Stool Antigen Test
  • 8.5.1. Enzyme Immunoassay
  • 8.5.2. Lateral Flow Immunoassay
• 8.6. Urea Breath Test
  • 8.6.1. 13C Urea Breath Test
  • 8.6.2. 14C Urea Breath Test

9. Helicobacter Pylori Diagnostics Market, by Product Type

• 9.1. Consumables
  • 9.1.1. Kits
    • 9.1.1.1. PCR Kits
    • 9.1.1.2. Rapid Urease Test Kits
    • 9.1.1.3. Serology Test Kits
    • 9.1.1.4. Stool Antigen Test Kits
    • 9.1.1.5. Urea Breath Test Kits
  • 9.1.2. Reagents
  • 9.1.3. Test Strips
• 9.2. Instruments
  • 9.2.1. Analyzer Equipment
    • 9.2.1.1. Breath Test Analyzers
    • 9.2.1.2. Immunoassay Analyzers
    • 9.2.1.3. PCR Instruments
  • 9.2.2. Endoscopy Systems

10. Helicobacter Pylori Diagnostics Market, by Technology

• 10.1. Invasive
  • 10.1.1. Culture
  • 10.1.2. Histology
  • 10.1.3. Rapid Urease Test
• 10.2. Noninvasive
  • 10.2.1. Antigen Test
  • 10.2.2. Breath Test
    • 10.2.2.1. Stool Antigen Test
    • 10.2.2.2. Urea Breath Test
  • 10.2.3. Molecular
  • 10.2.4. Serology

11. Helicobacter Pylori Diagnostics Market, by End User

• 11.1. Ambulatory Care Centers
  • 11.1.1. Community Health Centers
  • 11.1.2. Outpatient Clinics
• 11.2. Clinics
  • 11.2.1. Primary Care Clinics
  • 11.2.2. Specialty Clinics
• 11.3. Diagnostic Laboratories
  • 11.3.1. Commercial Laboratories
  • 11.3.2. Reference Laboratories
• 11.4. Hospitals
  • 11.4.1. Large Hospitals
  • 11.4.2. Small Hospitals

12. Helicobacter Pylori Diagnostics Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Helicobacter Pylori Diagnostics Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Helicobacter Pylori Diagnostics Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. United States Helicobacter Pylori Diagnostics Market

16. China Helicobacter Pylori Diagnostics Market

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025
• 17.5. Abbott Laboratories
• 17.6. Alpha Laboratories Ltd.
• 17.7. Becton, Dickinson and Company
• 17.8. Bio-Rad Laboratories, Inc.
• 17.9. bioMerieux SA
• 17.10. Certest Biotec S.L.
• 17.11. Coris BioConcept
• 17.12. DiaSorin S.p.A.
• 17.13. Eiken Chemical Co., Ltd.
• 17.14. Epitope Diagnostics, Inc.
• 17.15. F. Hoffmann-La Roche Ltd
• 17.16. Fujirebio Diagnostics, Inc.
• 17.17. Meridian Bioscience, Inc.
• 17.18. Quest Diagnostics Incorporated
• 17.19. QuidelOrtho Corporation
• 17.20. Savyon Diagnostics Ltd.
• 17.21. Sekisui Diagnostics LLC
• 17.22. Siemens Healthineers AG
• 17.23. Thermo Fisher Scientific Inc.